AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Ataxia - Pipeline Insight, 2019 - ResearchAndMarkets.com

March 13, 2019

DUBLIN--(BUSINESS WIRE)--Mar 13, 2019--The “Ataxia - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Ataxia - Pipeline Insight, 2019 offers comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Ataxia development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development for the Ataxia
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Ataxia
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Ataxia
  • The report also covers the dormant and discontinued pipeline projects related to Ataxia

Topics Covered

1. Report Introduction

2. Ataxia Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Ataxia

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Companies Featured

  • AbbVie
  • Adverum Biotechnologies Inc.
  • Agilis Biotherapeutics
  • Bach Pharma
  • Baxter Healthcare Corporation
  • BioBlast Pharma
  • Biohaven Pharma
  • Biovista
  • Cardero Therapeutics Inc.
  • Catabasis Pharmaceuticals
  • Edison Pharmaceuticals
  • Ixchel Pharma
  • Jupiter Orphan Therapeutics
  • Kissei Pharmaceutical Co. Ltd.
  • Neuraltus Pharmaceuticals
  • NsGene
  • Pfizer
  • ProQR Therapeutics
  • Rana Therpeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bc3kh9/ataxia_pipeline?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190313005385/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/13/2019 07:42 AM/DISC: 03/13/2019 07:42 AM

http://www.businesswire.com/news/home/20190313005385/en